Literature DB >> 7505876

Evaluation of six tumor markers in patients with carcinoma of unknown primary.

N Pavlidis1, J Kalef-Ezra, E Briassoulis, D Skarlos, P Kosmidis, K Saferiadis, E Bairaktari, D Bafaloukos, A Maravegias, D Theoharis.   

Abstract

We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19-9, CA 15-3, CA 125, beta-chorionic gonadotropin (beta-HCG) and alpha-fetoprotein (AFP) were related with the histological pattern (undifferentiated carcinoma or adenocarcinoma), the number and the site of metastases, as well as the response to chemotherapy and the patients' survival. More than 40% of the patients had increased serum levels of all six tumor markers, except of AFP which was found to be increased in only 17% of them. Increased levels of CA 19-9 were related to metastatic adenocarcinoma, whereas CA 19-9 and CA 15-3 had a relationship with more advanced disease. Patients with liver involvement had higher mean levels of CEA and CA 19-9 as compared to those with nodal disease. None of these markers was found to have a predictive value for response to chemotherapy or survival. Although the present study has a retrospective nature, it allows us to conclude that patients with CUP have a nonspecific over-expression of the above serum tumor markers and that routine use of these markers does not offer any diagnostic or prognostic assistance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7505876     DOI: 10.1002/mpo.2950220303

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  6 in total

1.  Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy.

Authors:  Kan Yonemori; Masashi Ando; Taro Shibata; Noriyuki Katsumata; Koji Matsumoto; Yasuhiro Yamanaka; Tsutomu Kouno; Chikako Shimizu; Yasuhiro Fujiwara
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-22       Impact factor: 4.553

2.  Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.

Authors:  C S Karapetis; D Yip; K Virik; A Strickland; K Ryder; M Cowling; P G Harper
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

3.  Carcinoma of unknown primary origin.

Authors:  Gauri R Varadhachary
Journal:  Gastrointest Cancer Res       Date:  2007-11

4.  A case of inguinal lymph node squamous cell carcinoma of unknown origin, accompanied with carcinoma in situ of cervix.

Authors:  Sung-Ha Lee; Min-Jung Kim; Hee-Jung Lee; Sa-Jin Kim; Jong-Sup Park; Soo-Young Hur
Journal:  J Gynecol Oncol       Date:  2008-06-20       Impact factor: 4.401

Review 5.  Cancer of Unknown Primary in the Molecular Era.

Authors:  Shumei Kato; Ahmed Alsafar; Vighnesh Walavalkar; John Hainsworth; Razelle Kurzrock
Journal:  Trends Cancer       Date:  2021-01-28

Review 6.  The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review.

Authors:  Ondřej Kubeček; Jan Laco; Jiří Špaček; Jiří Petera; Jindřich Kopecký; Alena Kubečková; Stanislav Filip
Journal:  Clin Exp Metastasis       Date:  2017-07-20       Impact factor: 5.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.